PD-L1 (CPS) >= 5
About
Biomarker type: Protein expression
Marker: PD-L1
Unit: Combined Positive Score (CPS)
Equality: >=
Value: 5
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) HSE (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin | |
| EMA (1) HSE (1) | HER2-negative, PD-L1 (CPS) >= 5 | Adenocarcinoma of the Gastroesophageal Junction | Fluorouracil, Nivolumab, Oxaliplatin | |
| EMA (1) HSE (1) | HER2-negative, PD-L1 (CPS) >= 5 | Stomach Adenocarcinoma | Capecitabine, Nivolumab, Oxaliplatin | |
| EMA (1) HSE (1) | HER2-negative, PD-L1 (CPS) >= 5 | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Nivolumab, Oxaliplatin | |
| EMA (1) HSE (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Capecitabine, Nivolumab, Oxaliplatin | |
| EMA (1) HSE (1) | HER2-negative, PD-L1 (CPS) >= 5 | Stomach Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin |